Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

PT101 is an engineered IL-2 mutein fused to a protein backbone ... that are trying to flip that on its head and try to use the cytokine to protect organs from autoimmune reactions.

Researchers from Rice University and Baylor College of Medicine have demonstrated a groundbreaking treatment that eradicates ...

Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide ...

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 ...

Data continues to differentiate ‘1104 as a potential allergic disease treatment that acts upstream in the immune cascade‘1104 reduces key indices of skin inflammation and inflammatory mediators in a ...

Rice University and Baylor College of Medicine have received $2.8 million in funding from the National Heart, Lung, and Blood ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

A groundbreaking clinical trial testing QH104, an allogeneic B7H3-targeting CAR-γδT cell therapy, has shown promising results ...

Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...